Fc-Engineered Anti-4-1BB Antibodies Pack a One-Two Punch.
A key issue in immuno-oncology is how to optimize and combine antibody therapies for improved efficacy. In this issue of Immunity, Buchan et al. (2018) reveal the importance of antibody Fc region, Fc receptor availability, and sequence of administration for optimal cancer therapy with antibodies targeting the co-stimulatory receptor 4-1BB.